A Single Arm Phase I-II Multicenter Trial With Avelumab Plus Autologous Dendritic Cell Vaccine to Determine Safety and Preliminary Efficacy of the Combination in Pre-treated Mismatch Repair-proficient (MSS) Metastatic Colorectal Cancer Patients.
Phase of Trial: Phase I/II
Latest Information Update: 23 Oct 2018
At a glance
- Drugs Avelumab (Primary) ; Dendritic cell vaccines
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms AVEVAC
- 31 Aug 2018 Biomarkers information updated
- 09 May 2018 Status changed from not yet recruiting to recruiting.
- 22 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Feb 2018.